Insulin eye drops are still largely an area of research and have not yet been widely adopted or approved for therapeutic clinical use. Insulin, a natural hormone that regulates blood sugar, has been investigated for its potential ocular applications due to its known growth factor properties which can stimulate cell growth and regeneration. Preliminary studies have explored using insulin eye drops to treat various corneal disorders, which rely on the ability of insulin to promote corneal epithelial healing. Conditions such as diabetic keratopathy, persistent epithelial defects, and dry eye disease are potential targets for this treatment modality. However, while the findings so far seem promising, more comprehensive and large-scale clinical trials are necessary to clearly establish the safety and efficacy of insulin eye drops. Additionally, a standardization of the formulation, concentration, and dosing regimen of insulin eye drops requires further research. It is crucial that patients continue using their prescribed treatments and consult with an eye care professional for guidance on any alternative therapies or experimental treatments.

NEWS FLASH:

Topical Insulin for Glaucoma

Trial ID: NCT05206877

Stanford Investigator(s)

Jeffrey Goldberg, MD, PhD

Blumenkranz Smead Professor

Author

Paddy Kalish OD, JD and B.Arch